INT80872

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.92
First Reported 1999
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 28
Total Number 28
Disease Relevance 10.56
Pain Relevance 8.62

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Nfkbia) plasma membrane (Nfkbia) nucleus (Nfkbia)
enzyme binding (Nfkbia) protein complex (Nfkbia) cytoplasm (Nfkbia)
Anatomy Link Frequency
endothelial cells 2
leukocytes 1
nucleus 1
astrocytes 1
mast cells 1
Nfkbia (Rattus norvegicus)
Pain Link Frequency Relevance Heat
diclofenac 6 99.74 Very High Very High Very High
aspirin 50 99.08 Very High Very High Very High
COX2 6 98.78 Very High Very High Very High
cytokine 22 98.44 Very High Very High Very High
Inflammation 56 98.08 Very High Very High Very High
cINOD 26 96.36 Very High Very High Very High
dexamethasone 8 96.12 Very High Very High Very High
Analgesic 11 94.72 High High
Migraine 7 93.72 High High
Central nervous system 6 89.44 High High
Disease Link Frequency Relevance Heat
Stomach Cancer 6 98.64 Very High Very High Very High
Necrosis 9 98.18 Very High Very High Very High
INFLAMMATION 67 98.08 Very High Very High Very High
Cancer 15 98.00 Very High Very High Very High
Nociception 2 94.40 High High
Skin Cancer 5 93.92 High High
Headache 7 93.72 High High
Myocardial Infarction 4 91.76 High High
Colon Cancer 4 89.56 High High
Adhesions 14 88.52 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Investigating the molecular mechanisms by which parthenolide prevents iNOS/NO synthesis, we found that parthenolide inhibits the activation of p42/44 mitogen-activated protein kinase (MAPK), but not IkBalpha (IkappaBalpha) degradation or nuclear factor-kappaB (NF-kappaB) p65 activation.
Protein_catabolism (degradation) of IkBalpha
1) Confidence 0.92 Published 2002 Journal J. Neuroimmunol. Section Abstract Doc Link 12417429 Disease Relevance 0.32 Pain Relevance 0.29
Investigating the molecular mechanisms by which parthenolide prevents iNOS/NO synthesis, we found that parthenolide inhibits the activation of p42/44 mitogen-activated protein kinase (MAPK), but not IkBalpha (IkappaBalpha) degradation or nuclear factor-kappaB (NF-kappaB) p65 activation.
Protein_catabolism (degradation) of IkappaBalpha
2) Confidence 0.80 Published 2002 Journal J. Neuroimmunol. Section Abstract Doc Link 12417429 Disease Relevance 0.32 Pain Relevance 0.28
The data also showed that NF-kappaB activation and its associated gene expressions, such as COX-2, iNOS, VCAM-1 and ICAM-1, were all suppressed by the low dose aspirin supplementation through the inhibition of phosphorylation and degradation of IkappaBalpha via the NIK/IKK pathway.
Protein_catabolism (degradation) of IkappaBalpha associated with aspirin
3) Confidence 0.75 Published 2006 Journal Mech. Ageing Dev. Section Abstract Doc Link 16310244 Disease Relevance 0.55 Pain Relevance 0.57
Furthermore, MEXS inhibited nuclear factor kappa B (NF-kappaB) DNA binding activity and the translocation of NF-kappaB to the nucleus by blocking the degradation of inhibitor of kappa B-alpha (IkappaB-alpha).
Protein_catabolism (degradation) of kappa B-alpha in nucleus
4) Confidence 0.17 Published 2005 Journal Biol. Pharm. Bull. Section Abstract Doc Link 15635170 Disease Relevance 0.66 Pain Relevance 0.23
NF-kappaB is activated by IkappaBalpha, its inhibitor, which is phosphorylated and proteolytically degraded.
Protein_catabolism (degraded) of IkappaBalpha
5) Confidence 0.16 Published 2000 Journal Med. Hypotheses Section Abstract Doc Link 10790762 Disease Relevance 0.10 Pain Relevance 0.46
NF-kappaB is activated by IkappaBalpha, its inhibitor, which is phosphorylated and proteolytically degraded.
Protein_catabolism (degraded) of IkappaBalpha
6) Confidence 0.15 Published 2000 Journal Med. Hypotheses Section Abstract Doc Link 10790762 Disease Relevance 0.10 Pain Relevance 0.46
Piperine blocks the phosphorylation and degradation of IkappaBalpha by attenuating TNF-alpha induced IkappaB kinase activity.
Protein_catabolism (degradation) of IkappaBalpha
7) Confidence 0.13 Published 2007 Journal Eur. J. Pharmacol. Section Abstract Doc Link 17764673 Disease Relevance 0.68 Pain Relevance 0.19
We observed that pretreatment of endothelial cells with piperine blocks the nuclear translocation and activation of NF-kappaB via blocking the phosphorylation and degradation of its inhibitory protein, IkappaBalpha.
Protein_catabolism (degradation) of IkappaBalpha in endothelial cells
8) Confidence 0.13 Published 2007 Journal Eur. J. Pharmacol. Section Abstract Doc Link 17764673 Disease Relevance 0.72 Pain Relevance 0.19
All drugs inhibited IkappaBalpha kinase and suppressed IkappaBalpha degradation and NF-kappaB-regulated reporter gene expression.
Protein_catabolism (degradation) of IkappaBalpha
9) Confidence 0.13 Published 2004 Journal Oncogene Section Abstract Doc Link 15489888 Disease Relevance 0.56 Pain Relevance 0.66
IkappaBalpha degradation, NF-kappaB activation, and iNOS expression were attenuated by parthenolide (3mg/kg), the active constituent of feverfew, an anti-inflammatory drug used for migraine treatment.
Protein_catabolism (degradation) of IkappaBalpha associated with inflammation and migraine
10) Confidence 0.11 Published 2002 Journal Ann. Neurol. Section Abstract Doc Link 11921057 Disease Relevance 0.70 Pain Relevance 0.56
Diclofenac induced the degradation of IkappaBalpha, which increased free nuclear factor kappaB (NF-kappaB) in cells.
Protein_catabolism (degradation) of IkappaBalpha associated with diclofenac
11) Confidence 0.11 Published 2005 Journal FEBS Lett. Section Abstract Doc Link 16051228 Disease Relevance 0.34 Pain Relevance 0.44
Our results indicate that CPDHC inhibits the NF-kappaB pathway by preventing the phosphorylation and proteolytic degradation of the IkappaBalpha protein.
Protein_catabolism (degradation) of IkappaBalpha
12) Confidence 0.10 Published 2000 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 11027495 Disease Relevance 0.07 Pain Relevance 0.09
Arvanil also prevents tumor necrosis factor-alpha-induced nuclear factor-kappaB (NF-kappaB) activation by direct inhibition of IkappaBalpha degradation, NF-kappaB binding to DNA, and NF-kappaB-dependent transcription.
Protein_catabolism (degradation) of IkappaBalpha associated with necrosis and cancer
13) Confidence 0.10 Published 2006 Journal Mol. Pharmacol. Section Abstract Doc Link 16394182 Disease Relevance 0.41 Pain Relevance 0.31
The transcription factor nuclear factor-kappaB (NF-kappaB) is constitutively activated in malignancies from enhanced activity of inhibitor of NF-kappaB (IkappaB) kinase, with accelerated IkappaBalpha degradation.
Protein_catabolism (degradation) of IkappaBalpha
14) Confidence 0.10 Published 2001 Journal Am. J. Physiol., Cell Physiol. Section Abstract Doc Link 11171586 Disease Relevance 0.30 Pain Relevance 0.08
The present study demonstrates that 1) inhibitory effect of dexamethasone on cytokine-induced iNOS expression and NO production in rat VSMCs, although potentially acting at multiple levels, is partly mediated by inhibition of NF-kappaB activation resulting from decreased phosphorylation and degradation of IkappaB-alpha, 2) both salicylate and aspirin inhibit cytokine-stimulated NO production at translational and/or posttranslational levels without affecting NF-kappaB- mediated iNOS gene expression, and 3) aspirin directly inhibits iNOS enzyme activity.
Protein_catabolism (degradation) of IkappaB-alpha associated with aspirin, dexamethasone and cytokine
15) Confidence 0.09 Published 1999 Journal Endocrinology Section Abstract Doc Link 10218970 Disease Relevance 0 Pain Relevance 0.70
NF-kappaB activation was detected using Western blotting to follow degradation of IkappaBalpha and nuclear localization of the p65 subunit of NF-kappaB.
Protein_catabolism (degradation) of IkappaBalpha
16) Confidence 0.06 Published 2009 Journal Lasers Surg Med Section Body Doc Link 19347944 Disease Relevance 0.15 Pain Relevance 0
Because activation of NF-kappaB requires proteolytic degradation of IkappaB by the ubiquitin-proteasome pathway of intracellular proteolysis, treatment with proteasome inhibitors was evaluated for efficacy in preventing NSAID gastropathy.
Protein_catabolism (degradation) of IkappaB associated with cinod
17) Confidence 0.04 Published 1999 Journal Gastroenterology Section Abstract Doc Link 10092308 Disease Relevance 0.41 Pain Relevance 0.26
Western blot analyses showed that both L-lactic acid and LcS culture supernatants suppressed phosphorylation and degradation of I-kappaB-alpha induced by LPS without affecting expression of TLR4.
Protein_catabolism (degradation) of I-kappaB-alpha
18) Confidence 0.03 Published 2009 Journal Am. J. Physiol. Gastrointest. Liver Physiol. Section Abstract Doc Link 19589943 Disease Relevance 0.76 Pain Relevance 0.03
We show that inhibition of NF-kappaB activation by tepoxalin is mediated by preventing IkappaB-alpha degradation.
Protein_catabolism (degradation) of IkappaB-alpha
19) Confidence 0.03 Published 1999 Journal Neuropharmacology Section Abstract Doc Link 10471086 Disease Relevance 0.40 Pain Relevance 0.39
The non-steroidal anti-inflammatory drug tepoxalin inhibits interleukin-6 and alpha1-anti-chymotrypsin synthesis in astrocytes by preventing degradation of IkappaB-alpha.
Protein_catabolism (degradation) of IkappaB-alpha in astrocytes associated with inflammation
20) Confidence 0.03 Published 1999 Journal Neuropharmacology Section Title Doc Link 10471086 Disease Relevance 0.51 Pain Relevance 0.42

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox